{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:12Z","timestamp":1792036812852,"version":"4.4.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Elranatamab, a bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, has shown significant efficacy in relapsed or refractory multiple myeloma (RRMM). However, elranatamab therapy also carries a risk of hematologic toxicity. Stem cell boost (SCB), involving reinfusion of previously collected autologous CD34\n                    <jats:sup>+<\/jats:sup>\n                    hematopoietic stem cells, has been explored as a salvage strategy after Chimeric Antigen Receptor T-cell (CAR T-cell) therapy-related cytopenias. To date, its role following bispecific antibody treatment remains unclear. We report the case of a 59-year-old man with RRMM who developed prolonged pancytopenia after elranatamab therapy, successfully rescued with autologous SCB. Neutrophil recovery occurred by day +10, transfusion independence by day +19, and hematologic recovery allowed elranatamab resumption without recurrence of severe cytopenia. This case demonstrates the potential utility of SCB for managing persistent cytopenias after T-cell\u2013redirecting therapies and supports the importance of early stem cell collection.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2025.1705843","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:31:30Z","timestamp":1767591090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case Report: autologous stem cell boost enables hematopoietic recovery after severe cytopenia induced by BCMA-targeted bispecific antibody therapy in multiple myeloma"],"prefix":"10.3389","volume":"15","author":[{"given":"Hiroaki","family":"Akiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Kakiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimasa","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naru","family":"Tomigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shutaro","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Harima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikumi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kozuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice for recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017415","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007776","article-title":"Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy","volume":"6","author":"Rejeski","year":"2022","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007572","article-title":"CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy","volume":"6","author":"Mullanfiroze","year":"2022","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.05.012","article-title":"Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA-directed CAR T-cell therapy","volume":"29","author":"Davis","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012522","article-title":"Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma","volume":"8","author":"Palacios-Berraquero","year":"2024","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008042","article-title":"Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA\/DRST study","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02482-6","article-title":"International Myeloma Working Group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e432204","DOI":"10.1200\/EDBK_432204","article-title":"Charting the course: sequencing immunotherapy for multiple myeloma","volume":"44","author":"Mohan","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091514","article-title":"T-cell redirecting therapies in multiple myeloma: pathogenesis and management of toxicities beyond CRS and ICANS","volume":"17","author":"Mancuso","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286027","article-title":"Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies","volume":"110","author":"Beyar-Katz","year":"2025","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with multiple myeloma receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-44080-9_16","article-title":"Mobilization and collection of HSC","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Worel","year":"2024"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701831","article-title":"Factors affecting autologous peripheral blood stem cell collection in patients with solid tumors","volume":"24","author":"Gandhi","year":"1999","journal-title":"Bone Marrow Transpl"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700771","article-title":"An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after myeloablative chemotherapy","volume":"19","author":"Weaver","year":"1997","journal-title":"Bone Marrow Transpl"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/09636897211036004","article-title":"Long-term cryopreservation does not affect quality of peripheral blood stem cell grafts: a comparative study of native, short-term and long-term cryopreserved haematopoietic stem cells","volume":"30","author":"Lysak","year":"2021","journal-title":"Cell Transpl"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3109\/14653241003745896","article-title":"Viability and engraftment of hematopoietic progenitor cells after long-term cryopreservation: effect of diagnosis and percentage dimethyl sulfoxide concentration","volume":"12","author":"Veeraputhiran","year":"2010","journal-title":"Cytotherapy"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1705843\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:31:31Z","timestamp":1767591091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1705843\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":20,"alternative-id":["10.3389\/fonc.2025.1705843"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1705843","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1705843"}}